Current Allergy and Asthma Reports

, Volume 6, Issue 5, pp 395–401 | Cite as

Update on toll-like receptor ligands and allergy: Implications for immunotherapy



Innate responses to microbes are mediated in large part via toll-like receptors (TLRs) that recognize a diverse family of ligands produced by viruses, bacteria, and fungi. Great effort has been directed toward translating this knowledge into the development of therapies for the prevention and treatment of diseases, including those fueled by allergic (Th2-biased) hypersensitivities. In this review, we consider the ways in which ligands for different TLRs influence the allergic phenotype. In addition, an update on safety and efficacy data from clinical trials of allergic patients treated with TLR9 ligand-based interventions is provided. Finally, recent experimental results that help elucidate how ambient TLR ligand exposures influence allergic risk and their relevance to the development of TLR ligand-based therapeutics are discussed. Investigations presented within this opinion paper suggest that several TLR ligands could have clinical utility in the treatment of allergic diseases, whereas other TLR ligands appear less attractive, as they facilitate development of Th2-biased hypersensitivities in murine studies.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Medzhitov R, Janeway CA Jr: Decoding the patterns of self and nonself by the innate immune system. Science 2002, 296:298–300.PubMedCrossRefGoogle Scholar
  2. 2.
    Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006, 124:783–801. This review provides an up-to-date and comprehensive review of the molecular pathways by which TLRs activate host immunity. In addition, Akira et al. discuss current understanding of TLR independent pathways by which PAMPS activate host immunity.PubMedCrossRefGoogle Scholar
  3. 3.
    Hoebe K, Janssen E, Beutler B: The interface between innate and adaptive immunity. Nat Immunol 2004, 5:971–974.PubMedCrossRefGoogle Scholar
  4. 4.
    Rifkin IR, Leadbetter EA, Busconi L, et al.: Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005, 204:27–42. A comprehensive review of endogenous TLR ligand production and its potential role in the pathogenesis of autoimmune diseases.PubMedCrossRefGoogle Scholar
  5. 5.
    Ishii KJ, Akira S: Innate immune recognition of nucleic acids: beyond toll-like receptors. Int J Cancer 2005, 117:517–523.PubMedCrossRefGoogle Scholar
  6. 6.
    Chisholm D, Libet L, Hayashi T, Horner AA: Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. J Allergy Clin Immunol 2004, 113:448–454.PubMedCrossRefGoogle Scholar
  7. 7.
    Moynagh PN: TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 2005, 26:469–476.PubMedCrossRefGoogle Scholar
  8. 8.
    Tulic MK, Wale JL, Holt PG, Sly PD: Modification of the inflammatory response to allergen challenge after exposure to bacterial lipopolysaccharide. Am J Respir Cell Mol Biol 2000, 22:604–612.PubMedGoogle Scholar
  9. 9.
    Eisenbarth SC, Piggott DA, Huleatt JW, et al.: Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002, 196:1645–1651.PubMedCrossRefGoogle Scholar
  10. 10.
    Kaisho T, Hoshino K, Iwabe T, et al.: Endotoxin can induce MyD88-deficient dendritic cells to support T(h)2 cell differentiation. Int Immunol 2002, 14:695–700.PubMedCrossRefGoogle Scholar
  11. 11.
    Horner AA, Raz E: Do microbes influence the pathogenesis of allergic diseases? Building the case for Toll-like receptor ligands. Curr Opin Immunol 2003, 15:614–619.PubMedCrossRefGoogle Scholar
  12. 12.
    Horner AA, Raz E: Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. J Allergy Clin Immunol 2002, 110:706–712.PubMedCrossRefGoogle Scholar
  13. 13.
    Kobayashi H, Horner AA, Takabayashi K, et al.: Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity. Cell Immunol 1999, 198:69–75.PubMedCrossRefGoogle Scholar
  14. 14.
    Rhee CS, Libet L, Chisholm D, et al.: Allergen-independent immunostimulatory sequence oligodeoxynucleotide therapy attenuates experimental allergic rhinitis. Immunology 2004, 113:106–113.PubMedCrossRefGoogle Scholar
  15. 15.
    Broide DH, Stachnick G, Castaneda D, et al.: Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J Clin Immunol 2001, 21:175–182.PubMedCrossRefGoogle Scholar
  16. 16.
    Horner AA, Widhopf GF, Burger JA, et al.: Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells. J Allergy Clin Immunol 2001, 108:417–423.PubMedCrossRefGoogle Scholar
  17. 17.
    Hayashi T, Beck L, Rossetto C, et al.: Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 2004, 114:270–279. A novel and potentially important pathway by which ISS-ODN and other TLR ligands might impact on the allergic phenotype is described.PubMedCrossRefGoogle Scholar
  18. 18.
    Hessel EM, Chu M, Lizcano JO, et al.: Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J Exp Med 2005, 202:1563–1573.PubMedCrossRefGoogle Scholar
  19. 19.
    Takabayashi K, Libet L, Chisholm D, et al.: Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in th2-sensitized mice. J Immunol 2003, 170:3898–3905.PubMedGoogle Scholar
  20. 20.
    Halperin SA, Van Nest G, Smith B, et al.: A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003, 21:2461–2467.PubMedCrossRefGoogle Scholar
  21. 21.
    Racila DM, Kline JN: Perspectives in asthma: molecular use of microbial products in asthma prevention and treatment. J Allergy Clin Immunol 2005, 116:1202–1205.PubMedCrossRefGoogle Scholar
  22. 22.
    Horner AA, Takabayashi K, Beck L, et al.: Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J Allergy Clin Immunol 2002, 110:413–420.PubMedCrossRefGoogle Scholar
  23. 23.
    Tighe H, Takabayashi K, Schwartz D, et al.: Conjugation of protein to immunostimulatory DNA results in a rapid, longlasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 2000, 30:1939–1947.PubMedCrossRefGoogle Scholar
  24. 24.
    Creticos PS, Eiden JJ, Balcer SL, et al.: Immunostimulatory oligodeoxynucleotides conjugated to Amb a 1: safety, skin test reactivity, and basophil histamine release [abstract]. J Allergy Clin Immunol 2000, 105:S70.CrossRefGoogle Scholar
  25. 25.
    Simons FE, Shikishima Y, Van Nest G, et al.: Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004, 113:1144–1151.PubMedCrossRefGoogle Scholar
  26. 26.
    Tulic MK, Fiset PO, Christodoulopoulos P, et al.: Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004, 113:235–241. This paper provides the first published evidence that ISS-ODN conjugated allergens have clinical efficacy in the treatment of allergic rhinitis.PubMedCrossRefGoogle Scholar
  27. 27.
    Redecke V, Hacker H, Datta SK, et al.: Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol 2004, 172:2739–2743.PubMedGoogle Scholar
  28. 28.
    Agrawal S, Agrawal A, Doughty B, et al.: Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003, 171:4984–4989.PubMedGoogle Scholar
  29. 29.
    Patel M, Xu D, Kewin P, et al.: TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J Immunol 2005, 174:7558–7563.PubMedGoogle Scholar
  30. 30.
    McCurdy JD, Olynych TJ, Maher LH, Marshall JS: Cutting edge: distinct toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol 2003, 170:1625–1629.PubMedGoogle Scholar
  31. 31.
    Re F, Strominger JL: Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001, 276:37692–37699.PubMedCrossRefGoogle Scholar
  32. 32.
    Supajatura V, Ushio H, Nakao A, et al.: Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 2002, 109:1351–1359.PubMedCrossRefGoogle Scholar
  33. 33.
    Boguniewicz M, Leung DY: Pathophysiologic mechanisms in atopic dermatitis. Semin Cutan Med Surg 2001, 20:217–225.PubMedCrossRefGoogle Scholar
  34. 34.
    Matsui K, Nishikawa A: Lipoteichoic acid from Staphylococcus aureus induces Th2-prone dermatitis in mice sensitized percutaneously with an allergen. Clin Exp Allergy 2002, 32:783–788.PubMedCrossRefGoogle Scholar
  35. 35.
    Wang L, Smith D, Bot S, et al.: Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J Clin Invest 2002, 110:1175–1184.PubMedCrossRefGoogle Scholar
  36. 36.
    Didierlaurent A, Ferrero I, Otten LA, et al.: Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol 2004, 172:6922–6930.PubMedGoogle Scholar
  37. 37.
    Brugnolo F, Sampognaro S, Liotta F, et al.: The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol 2003, 111:380–388.PubMedCrossRefGoogle Scholar
  38. 38.
    Abreu MT, Fukata M, Arditi M: TLR signaling in the gut in health and disease. J Immunol 2005, 174:4453–4460.PubMedGoogle Scholar
  39. 39.
    Braun-Fahrlander C, Riedler J, Herz U, et al.: Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002, 347:869–877.PubMedCrossRefGoogle Scholar
  40. 40.
    Frew AJ: Advances in environmental and occupational diseases 2004. J Allergy Clin Immunol 2005, 115:1197–1202.PubMedCrossRefGoogle Scholar
  41. 41.
    Platts-Mills TA, Woodfolk JA, Erwin EA, Aalberse R: Mechanisms of tolerance to inhalant allergens: the relevance of a modified Th2 response to allergens from domestic animals. Springer Semin Immunopathol 2004, 25:271–279.PubMedCrossRefGoogle Scholar
  42. 42.
    Gereda JE, Klinnert MD, Price MR, et al.: Metropolitan home living conditions associated with indoor endotoxin levels. J Allergy Clin Immunol 2001, 107:790–796.PubMedCrossRefGoogle Scholar
  43. 43.
    Gereda JE, Leung DY, Thatayatikom A, et al.: Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma. Lancet 2000, 355:1680–1683.PubMedCrossRefGoogle Scholar
  44. 44.
    Roy SR, Schiltz AM, Marotta A, et al.: Bacterial DNA in house and farm barn dust. J Allergy Clin Immunol 2003, 112:571–578.PubMedCrossRefGoogle Scholar
  45. 45.
    van Strien RT, Engel R, Holst O, et al.: Microbial exposure of rural school children, as assessed by levels of N-acetyl-muramic acid in mattress dust, and its association with respiratory health. J Allergy Clin Immunol 2004, 113:860–867.PubMedCrossRefGoogle Scholar
  46. 46.
    Saxon A, Diaz-Sanchez D: Air pollution and allergy: you are what you breathe. Nat Immunol 2005, 6:223–226.PubMedCrossRefGoogle Scholar
  47. 47.
    Boasen J, Chisholm D, Lebet L, et al.: House dust extracts elicit Toll-like receptor-dependent dendritic cell responses. J Allergy Clin Immunol 2005, 116:185–191. This paper provides the first direct evidence that sterile HDEs have TLR-dependent immunostimulatory activities.PubMedCrossRefGoogle Scholar
  48. 48.
    Ng N, Lam D, Paulus P, et al.: House dust extracts have both Th2 adjuvant and tolerogenic activities. J Allergy Clin Immunol 2006, 117:1074–1081. In this follow-up paper to Boasen et al. [47], we established that HDEs have both Th2-adjuvant and tolerogenic activities.PubMedCrossRefGoogle Scholar
  49. 49.
    Becker S, Fenton MJ, Soukup JM: Involvement of microbial components and toll-like receptors 2 and 4 in cytokine responses to air pollution particles. Am J Respir Cell Mol Biol 2002, 27:611–618.PubMedGoogle Scholar
  50. 50.
    Rabinovitch N, Liu AH, Zhang L, et al.: Importance of the personal endotoxin cloud in school-age children with asthma. J Allergy Clin Immunol 2005, 116:1053–1057.PubMedCrossRefGoogle Scholar
  51. 51.
    Alexis NE, Becker S, Bromberg PA, et al.: Circulating CD11b expression correlates with the neutrophil response and airway mCD14 expression is enhanced following ozone exposure in humans. Clin Immunol 2004, 111:126–131.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Departments of Medicine and Pediatrics and The Sam and Rose Stein Institute for AgingUniversity of California, San DiegoLa JollaUSA

Personalised recommendations